SCHEMBL30217836

SCHEMBL30217836

COCCOc1cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(C(=O)OC)c2nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.40
RET P07949 1/20 0.40
GPR119 Q8TDV5 3/20 0.40
KIT P10721 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
POLB P06746 1/20 0.38
PTPN11 Q06124 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
ACHE P22303 2/20 0.37
LMNA P02545 1/20 0.37
MAP4K4 O95819 1/20 0.37
SLC2A1 P11166 1/20 0.37
NR1H2 P55055 1/20 0.37
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25096370 1.00 BACE1 (0.40) BACE1RETGPR119KITSMARCA2
SCHEMBL25097076 0.92 GPR119 (0.42) BACE1RETGPR119KITSMARCA2
SCHEMBL30217579 0.92 GPR119 (0.42) BACE1RETGPR119KITSMARCA2
SCHEMBL30217858 0.89 SMARCA2 (0.42) BACE1GPR119KITSMARCA2SMARCA4
SCHEMBL25096775 0.89 SMARCA2 (0.42) BACE1GPR119KITSMARCA2SMARCA4
SCHEMBL25096369 0.88 BACE1 (0.42) BACE1RETGPR119KITSMARCA2
SCHEMBL30217822 0.88 BACE1 (0.42) BACE1RETGPR119KITSMARCA2
SCHEMBL30217876 0.86 BACE1 (0.41) BACE1RETGPR119KITPOLB
SCHEMBL29256966 0.86 BACE1 (0.41) BACE1RETGPR119KITPOLB
SCHEMBL30312627 0.84 SMARCA2 (0.42) BACE1KITSMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 BACE1 668/4885RET 4144/4885GPR119 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.